company background image
SWAV

ShockWave Medical NasdaqGS:SWAV Stock Report

Last Price

US$197.69

Market Cap

US$7.1b

7D

25.0%

1Y

1.9%

Updated

24 Jun, 2022

Data

Company Financials +
SWAV fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance3/6
Financial Health5/6
Dividends0/6

SWAV Stock Overview

ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide.

ShockWave Medical Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for ShockWave Medical
Historical stock prices
Current Share PriceUS$197.69
52 Week HighUS$249.73
52 Week LowUS$113.36
Beta1.48
1 Month Change18.53%
3 Month Change2.56%
1 Year Change1.86%
3 Year Change246.28%
5 Year Changen/a
Change since IPO548.16%

Recent News & Updates

Jun 06
Returns Are Gaining Momentum At ShockWave Medical (NASDAQ:SWAV)

Returns Are Gaining Momentum At ShockWave Medical (NASDAQ:SWAV)

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

Shareholder Returns

SWAVUS Medical EquipmentUS Market
7D25.0%7.0%6.6%
1Y1.9%-23.7%-18.5%

Return vs Industry: SWAV exceeded the US Medical Equipment industry which returned -25.1% over the past year.

Return vs Market: SWAV exceeded the US Market which returned -20.5% over the past year.

Price Volatility

Is SWAV's price volatile compared to industry and market?
SWAV volatility
SWAV Average Weekly Movement12.5%
Medical Equipment Industry Average Movement10.5%
Market Average Movement8.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: SWAV is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: SWAV's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2009657Doug Godshallhttps://www.shockwavemedical.com

ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors.

ShockWave Medical Fundamentals Summary

How do ShockWave Medical's earnings and revenue compare to its market cap?
SWAV fundamental statistics
Market CapUS$7.08b
Earnings (TTM)US$28.99m
Revenue (TTM)US$298.88m

244.1x

P/E Ratio

23.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SWAV income statement (TTM)
RevenueUS$298.88m
Cost of RevenueUS$46.44m
Gross ProfitUS$252.44m
Other ExpensesUS$223.46m
EarningsUS$28.99m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 08, 2022

Earnings per share (EPS)0.81
Gross Margin84.46%
Net Profit Margin9.70%
Debt/Equity Ratio6.5%

How did SWAV perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is SWAV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SWAV?

Other financial metrics that can be useful for relative valuation.

SWAV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue23.2x
Enterprise Value/EBITDA193.5x
PEG Ratio7.2x

Price to Sales Ratio vs Peers

How does SWAV's PS Ratio compare to its peers?

SWAV PS Ratio vs Peers
The above table shows the PS ratio for SWAV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average9.7x

Price-To-Sales vs Peers: SWAV is expensive based on its Price-To-Sales Ratio (23.7x) compared to the peer average (9.7x).


Price to Earnings Ratio vs Industry

How does SWAV's PE Ratio compare vs other companies in the U.S. Medical Equipment Industry?

Price-To-Sales vs Industry: SWAV is expensive based on its Price-To-Sales Ratio (23.7x) compared to the US Medical Equipment industry average (3.8x)


Price to Sales Ratio vs Fair Ratio

What is SWAV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SWAV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio23.7x
Fair PS Ratio16.8x

Price-To-Sales vs Fair Ratio: SWAV is expensive based on its Price-To-Sales Ratio (23.7x) compared to the estimated Fair Price-To-Sales Ratio (16.8x).


Share Price vs Fair Value

What is the Fair Price of SWAV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SWAV ($197.69) is trading above our estimate of fair value ($39.5)

Significantly Below Fair Value: SWAV is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: SWAV is poor value based on its PEG Ratio (7.2x)


Discover undervalued companies

Future Growth

How is ShockWave Medical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

6/6

Future Growth Score 6/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


33.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SWAV's forecast earnings growth (33.9% per year) is above the savings rate (1.9%).

Earnings vs Market: SWAV's earnings (33.9% per year) are forecast to grow faster than the US market (13.9% per year).

High Growth Earnings: SWAV's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SWAV's revenue (24.9% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: SWAV's revenue (24.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SWAV's Return on Equity is forecast to be high in 3 years time (28%)


Discover growth companies

Past Performance

How has ShockWave Medical performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


11.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SWAV has high quality earnings.

Growing Profit Margin: SWAV became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: SWAV has become profitable over the past 5 years, growing earnings by 11.9% per year.

Accelerating Growth: SWAV has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: SWAV has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: SWAV's Return on Equity (10.8%) is considered low.


Discover strong past performing companies

Financial Health

How is ShockWave Medical's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: SWAV's short term assets ($309.9M) exceed its short term liabilities ($51.0M).

Long Term Liabilities: SWAV's short term assets ($309.9M) exceed its long term liabilities ($53.7M).


Debt to Equity History and Analysis

Debt Level: SWAV has more cash than its total debt.

Reducing Debt: Insufficient data to determine if SWAV's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: SWAV's debt is well covered by operating cash flow (198.3%).

Interest Coverage: SWAV's interest payments on its debt are well covered by EBIT (29.6x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is ShockWave Medical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SWAV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SWAV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SWAV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SWAV's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SWAV has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Doug Godshall (56 yo)

5.08yrs

Tenure

US$7,317,042

Compensation

Mr. Douglas E. Godshall, also known as Doug, M.B.A., has been the Chief Executive Officer and President of Shockwave Medical, Inc. since May 10, 2017. Mr. Godshall serves as the Chairman at Saluda Medical...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD7.32M) is about average for companies of similar size in the US market ($USD8.47M).

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: SWAV's management team is considered experienced (4.3 years average tenure).


Board Members

Experienced Board: SWAV's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SWAV insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.


Top Shareholders

Company Information

ShockWave Medical, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: ShockWave Medical, Inc.
  • Ticker: SWAV
  • Exchange: NasdaqGS
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$7.076b
  • Shares outstanding: 35.79m
  • Website: https://www.shockwavemedical.com

Number of Employees


Location

  • ShockWave Medical, Inc.
  • 5403 Betsy Ross Drive
  • Santa Clara
  • California
  • 95054
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/24 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.